Boards need concrete evidence, not verbal assurance, that management actually controls AI liability accumulation across lines before the next renewal cycle locks in another year of exposure.
Anti-selection in digital life distribution deserves direct board scrutiny in life and health reinsurance. Here is how boards should evaluate whether this risk is genuinely under control.
API gaps broker cedant systems oversight starts with putting a real number on how much placement speed and pricing accuracy the current process actually costs.
Boards overseeing life and health reinsurers need specific, evidence-based questions to confirm management actually controls behavioral lapse models that fail in stress, not just assurances that it does.
Boards overseeing life and health reinsurers should not tolerate claims leakage in high-volume health portfolios without specific, quantified evidence of detection and remediation from management.
Boards need a clear answer to what would break first if cyber event definitions across multiple treaties stayed ambiguous through the next systemic event.
Boards overseeing health provider inflation hidden by network averages need a remediate, reprice, reduce, or exit test for underperforming provider exposures. Here is how to run it.
If institutional knowledge kept getting lost in workflow handoffs, renewal quality and dispute outcomes would be the first things to break, and boards should watch both closely.
Boards overseeing life and health reinsurance need an explicit risk-appetite limit for longevity concentration across pension transactions, not just trust in transaction-level review. Here is the test to apply.
Boards overseeing life and health reinsurance need a clear answer to what breaks first if medical trend outpacing treaty economics continues unchecked. Here is the governance question worth asking now.
Mortality improvement assumptions after structural shocks deserve direct board scrutiny in life and health reinsurance. Here are the questions a board should be asking and why.
A simple remediate, reprice, reduce, or exit test gives reinsurance boards a structured way to oversee privacy regulation fragmentation exposure instead of reviewing it in the abstract.
Renewal season is the real stress test for reporting cycles that take weeks instead of days, and boards should use it to find out how far behind their risk reporting actually falls.
Boards should require documented evidence, not general assurance, before accepting that silent technology exposure in legacy wordings is being managed rather than merely acknowledged.
A board-level renewal stress test is the clearest way to confirm systemic scenarios without action thresholds are not quietly slipping through governance oversight.
Boards need an explicit risk-appetite test for technology supply-chain dependencies before regulators or a real outage force the question onto the agenda.
Board oversight of treaty recapture decisions without customer impact analysis needs a renewal-season stress test. Here is what that test should cover.
Vendor lock-in technology agility oversight belongs on the board agenda because it is a continuity and capital risk, not just a technology preference.